USPTO serial 79334074
ADLAI NORTYE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 27, 2023
- Examiner
- BROWN, TINA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ADLAI NORTYE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Hangzhou Adlai Nortye Biopharma Co., Ltd.
CN
Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
Hangzhou Adlai Nortye Biopharma Co., Ltd.
CN
Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
Hangzhou Adlai Nortye Biopharma Co., Ltd.
CN
Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rita E. Kline
Rita E. Kline Renner, Otto, Boisselle & Sklar, LLP1621 Euclid Ave.Floor 19Cleveland, OH 44115Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemico-pharmaceutical preparations for the treatment of tumor, immune, and metabolic related diseases and disorders; injectable pharmaceutical preparations for the treatment of tumor, immune, and metabolic related diseases and disorders; injectable pharmaceutical solutions for medical purposes for treatment of tumor, immune, and metabolic related diseases and disorders; troche, namely, medicated lozenges; medicines based on biologically active substances for treatment of tumor, immune, and metabolic related diseases and disorders; blood substitutes for medical and veterinary use; medicines for human purposes for treatment of tumor, immune, and metabolic related diseases and disorders; drugs for medical purposes for treatment of tumor, immune, and metabolic related diseases and disorders; biological preparations for medical purposes for treatment of tumor, immune, and metabolic related diseases and disorders; stem cells for medical purposes; biochemical drug, namely, biochemical pharmaceutical preparations for the treatment of tumor, immune, and metabolic related diseases and disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
- Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
- Other trademarks owned by Hangzhou Adlai Nortye Biopharma Co., Ltd.
- Other trademarks in Class 005
- Similar marks named ADLAI NORTYE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 24, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 28, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 27, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 27, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 2, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 2, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 2, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 27, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 27, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 13, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 11, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 11, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 6, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 6, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 6, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 22, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 22, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 22, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 8, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 8, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 8, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 23, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 12, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 24, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 24, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 30, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 29, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 1, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 25, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 24, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |